Evidence map›Paper›PMID 19273186›Full record

ReviewFrontiers in bioscience (Landmark edition)2009

Ovarian cancer: pathology, biology, and disease models.

Daniel G Rosen, Gong Yang, Guangzhi Liu, Imelda Mercado-Uribe, Bin Chang, Xue Sherry Xiao, Jingfang Zheng, Feng-Xia Xue, Jinsong Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioscience (Landmark edition), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Suppression of GNAI2 message in ovarian cancer.Journal of ovarian research · 2014
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. LowTheranostics · 2024
    Article
  7. CircWHSC1 (CircNSD2): A Novel Circular RNA in Multiple Cancers.Clinical Medicine Insights. Oncology · 2024
    Review
  8. Gene polymorphisms ofJournal of Cancer · 2024
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel G RosenDepartment of Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77005-4095, USA.
Gong Yang
Guangzhi Liu
Imelda Mercado-Uribe
Bin Chang
Xue Sherry Xiao
Jingfang Zheng
Feng-Xia Xue
Jinsong Liu

Funding

RAS Signaling, Senescent Fibroblasts, and Ovarian Cancer ProgressionR01CA131183 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIU, JINSONG · 2008 to 2012
$1.3M
NCI NIH HHS 1R01CA131183-01A2NCI NIH HHS R01 CA131183
6 · The paper itself

Abstract

Epithelial ovarian cancer, which comprises several histologic types and grades, is the most lethal cancer among women in the United States. In this review, we summarize recent progress in understanding the pathology and biology of this disease and in development of models for preclinical research. Our new understanding of this disease suggests new targets for therapeutic intervention and novel markers for early detection of disease.

Indexed as

FemaleGenes, HomeoboxHumansOvarian Neoplasms

Identifiers

PMID19273186
PMCPMC2858969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.